

ASX Announcement

9 December 2025

BCAL to enable pancreatic and ovarian cancer early detection blood testing across Australia starting in January

Highlights

- **Avantect® early detection tests for pancreatic and ovarian cancer available to clinicians and patients from 19 January 2026**
- **Nationwide access will be facilitated via Sonic Healthcare's Australian pathology network**

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for the early detection of cancer, announces that patient testing on Avantect ovarian and pancreatic early detection blood tests will commence in January 2026.

The Avantect tests will be available in Australia through BCAL's partnership with **ClearNote Health**, announced in September 2025. Nationwide access will be facilitated through **Sonic Healthcare's** pathology network in coordination with BCAL's laboratory in North Ryde and ClearNote Health's testing facility in San Diego.

Physicians at the **Sydney Breast Clinic** will begin seeing patients on 19 January 2026 to discuss Avantect tests and their clinical relevance for patients. Avantect tests are based on epigenomic and genomic analyses of circulating DNA, coupled with state-of-the-art AI/ML algorithms. They have demonstrated strong predictive value in early-stage cancer patients where protein marker-based tests regularly fail.

Information regarding early-stage cancer detection and appointments with physicians are available at <https://earlydetection.com.au>.

BCAL CEO, Shane Ryan, said: *"For the first time, Australians will be able to access vital early-detection blood tests across the country. Pancreatic and ovarian cancers are considered 'silent killers' because they are often detected too late. Through early detection, physicians have a wider array of treatment options that can lead to profound increases in survival rates, so we are proud to have brought Avantect to the Australian market so quickly."*

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

BCAL CEO

Shane Ryan

sryan@bcaldiagnostics.com

+61 (0) 437 192 869

Media Relations

Rama Razy

rama.razy@automicgroup.com.au

+61 (0) 498 440 142

About Avantect

Avantect® [pancreatic](#) and [ovarian](#) diagnostic tests are highly sensitive, non-invasive and may identify cancers in high-risk patient populations earlier than conventional approaches, when patients may be more likely to benefit from treatment. Developed by scientists in the Stephen Quake laboratory at Stanford University, ClearNote Health's patented core [Virtuoso™ epigenomics platform](#) builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. ClearNote Health's headquarters and CLIA-certified, CAP-accredited laboratory are located in San Diego. For more information, visit www.clearnotehealth.com or follow the company on [LinkedIn](#).

About BCAL

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST*plus*™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST*plus*™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds the exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.